Despite the rise of a vaccine skeptic in the campaign of US presidential election winner Donald Trump, GSK CEO Emma Walmsley ...

GSK cut its full-year vaccine sales outlook after key shots for respiratory syncytial virus and shingles missed expectations ...

全球首家公布RSV候选疫苗与已获批重磅RSV疫苗头对头临床试验结果、且结果积极的厂家，来自中国。 当开年至今无一款国产创新型疫苗获批上市，二类疫苗又几乎迎来全员内卷、“价格战”四处打响时，中国创新疫苗行业终于传来了一则好消息：一款国产呼吸道合胞病毒（RSV）候选疫苗，头对头PK全球首款获批上市的RSV疫苗Arexvy，获得了积极的临床数据。

GSK has agreed to pay up to $2.2 billion to settle most lawsuits in US state courts claiming that a discontinued version of the heartburn drug Zantac caused cancer, the company announced on ...

(Reuters) -GSK (GSK) on Wednesday said its vaccine sales would fall this year, after a weaker-than-expected performance for its respiratory syncytial virus (RSV) and shingles vaccines in the third ...

GSK has stopped (PDF) development of one of the lead programs from its $2.1 billion Affinivax takeover, axing a phase 2 pneumococcal 24-valent vaccine candidate for adults in favor of a ...

上周，大事连连。 上半周，为期三天半的国家医保谈判顺利落幕，共涉及127家企业、162种药品，其中医保目录外药品117种，医保目录内谈判续约药品45种。新版医保药品目录预计于11月底对外发布，明年1月1日起正式实施。

在不少跨国药企宣布或传出分拆健康消费品业务的情况下，拜耳在中国持续加码健康消费品业务。 10月16日，拜耳健康消费品中国创新合作中心（China Center of Innovation and ...

GSK shares fell on Wednesday after the group's vaccine sales continued to disappoint in the third quarter. The drugmaker saw weaker-than-expected demand for its respiratory syncytial virus (RSV ...

Investing.com -- Shares of GSK fell over 3% following its third-quarter 2024 earnings, as investors reacted to underwhelming ...

周三，H.C. Wainwright调整了对AnaptysBio (NASDAQ: ANAB)的展望，将目标价从55.00美元下调至52.00美元，同时维持对该股的买入评级。该公司表示，此次调整是基于AnaptysBio第三季度的财务表现以及预计运营开支的增加。 AnaptysBio报告2024年第三季度总运营开支为5280万美元，较同年第二季度略有上升。本季度运营亏损为2280万美元，每股收益( ...